Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 5 for:    timeless
Previous Study | Return to List | Next Study

Tenecteplase in Stroke Patients Between 4.5 and 24 Hours (TIMELESS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03785678
Recruitment Status : Recruiting
First Posted : December 24, 2018
Last Update Posted : April 13, 2020
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.

Tracking Information
First Submitted Date  ICMJE December 19, 2018
First Posted Date  ICMJE December 24, 2018
Last Update Posted Date April 13, 2020
Actual Study Start Date  ICMJE March 2, 2019
Estimated Primary Completion Date November 30, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 20, 2018)
Ordinal modified Rankin scale (mRS) score [ Time Frame: Day 90 ]
The Efficacy of Tenecteplase compared to placebo is evaluated in terms of Ordinal mRS score at day 90.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 9, 2020)
  • Proportion of patients with functional independence [ Time Frame: Day 90 ]
    The efficacy of Tenecteplase is evaluated in terms of proportion of patients with functional independence, defined as an mRS of 0-2, at Day 90
  • Proportion of patients with angiographic reperfusion [ Time Frame: Day 1 ]
    The efficacy of Tenecteplase is evaluated in terms of proportion of patients with angiographic reperfusion at completion of angiographic procedure (endovascular patients only).
  • Median NIHSS score [ Time Frame: Day 90 ]
    The efficacy of Tenecteplase is evaluted in terms of Median NIHSS score at Day 90.
  • Proportion of patients with a Barthel Index (BI) score >=95 [ Time Frame: Day 90 ]
    The efficacy of Tenecteplase is evaluated in terms of Proportion of patients with a BI score >=95 at Day 90.
  • Proportion of patients with good recovery based on the Glasgow Outcome Scale (GOS) at Day 90 [ Time Frame: Day 90 ]
    The efficacy of Tenecteplase is evaluated in terms of the proportion of patients with good recovery based on the GOS at Day 90.
  • Proportion of patients with reperfusion at 24 hours post-randomization [ Time Frame: Day 2 ]
    The efficacy of Tenecteplase is evaluated in terms of proportion of patients with reperfusion at 24 hours post-randomization, defined as >90% reduction in Tmax>6s lesion volume
  • Proportion of patients with recanalization at 24 hours post-randomization [ Time Frame: Day 2 ]
    The efficacy of Tenecteplase is evaluated in terms of proportion of patients with recanalization at 24 hours post-randomization, defined as complete or partial recanalization on CT angiography (CTA)/magnetic resonance angiography (MRA).
  • Number of patients with symptomatic intracranial hemorrhage (sICH a) [ Time Frame: Day 2 ]
    The safety profile of Tenecteplase is evaluated in terms of number of patients with sICH within 36 hours
  • Incidence and severity of adverse events [ Time Frame: From baseline up to day 90 ]
    The safety profile of Tenecteplase is evaluated in terms of incidence and severity of adverse events.
  • Mortality rate at Day 30 and Day 90 [ Time Frame: Day 30 and Day 90 ]
    The safety profile of Tenecteplase is evaluated in terms of mortality rate at Day 30 and Day 90
  • Proportion of patients with parenchymal hematoma type 2 (PH2) at 72 hours [ Time Frame: Day 3 ]
    The safety profile of Tenecteplase is evaluated in terms of proportion of patients with PH2 at 72 hours
Original Secondary Outcome Measures  ICMJE
 (submitted: December 20, 2018)
  • Proportion of patients with functional independence [ Time Frame: Day 90 ]
    The efficacy of Tenecteplase is evaluated in terms of proportion of patients with functional independence, defined as an mRS of 0-2, at Day 90
  • Proportion of patients where planned thrombectomy was not performed [ Time Frame: within 90 minutes from the randomization ]
    The efficacy of Tenecteplase is evaluated in terms of proportion of patients where planned thrombectomy was not performed.
  • Proportion of patients with angiographic reperfusion [ Time Frame: Day 1 ]
    The efficacy of Tenecteplase is evaluated in terms of proportion of patients with angiographic reperfusion at completion of angiographic procedure (endovascular patients only).
  • Median NIHSS score [ Time Frame: Day 90 ]
    The efficacy of Tenecteplase is evaluted in terms of Median NIHSS score at Day 90.
  • Proportion of patients with a Barthel Index (BI) score >=95 [ Time Frame: Day 90 ]
    The efficacy of Tenecteplase is evaluated in terms of Proportion of patients with a BI score >=95 at Day 90.
  • Proportion of patients with a Glasgow Outcome Scale (GOS) of 1 at Day 90 [ Time Frame: Day 90 ]
    The efficacy of Tenecteplase is evaluated in terms of proportion of patients with GOS of 1 at Day 90.
  • Proportion of patients with reperfusion at 24 hours post-treatment [ Time Frame: Day 2 ]
    The efficacy of Tenecteplase is evaluated in terms of proportion of patients with reperfusion at 24 hours post-treatment, defined as >90% reduction in Tmax>6s lesion volume
  • Proportion of patients with recanalization at 24 hours post-treatment [ Time Frame: Day 2 ]
    The efficacy of Tenecteplase is evaluated in terms of proportion of patients with recanalization at 24 hours post-treatment, defined as complete or partial recanalization on CT angiography (CTA)/magnetic resonance angiography (MRA).
  • Number of patients with symptomatic intracranial hemorrhage (sICH a) [ Time Frame: Day 2 ]
    The safety profile of Tenecteplase is evaluated in terms of number of patients with sICH within 36 hours
  • Incidence and severity of adverse events [ Time Frame: From baseline up to day 90 ]
    The safety profile of Tenecteplase is evaluated in terms of incidence and severity of adverse events.
  • Mortality rate at Day 30 and Day 90 [ Time Frame: Day 30 and Day 90 ]
    The safety profile of Tenecteplase is evaluated in terms of mortality rate at Day 30 and Day 90
  • Proportion of patients with parenchymal hematoma type 2 (PH2) at 72 hours [ Time Frame: Day 3 ]
    The safety profile of Tenecteplase is evaluated in terms of proportion of patients with PH2 at 72 hours
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Tenecteplase in Stroke Patients Between 4.5 and 24 Hours
Official Title  ICMJE A Phase III, Prospective, Double-blind, Randomized, Placebo-controlled Trial of Thrombolysis in Imaging-eligible, Late-window Patients to Assess the Efficacy and Safety of Tenecteplase (TIMELESS)
Brief Summary

This study will evaluate the efficacy and safety of tenecteplase compared with placebo in patients with acute ischemic stroke (AIS). All patients will receive standard-of-care therapy according to American Heart Association / American Stroke Association clinical guidelines (2018). To determine eligibility for randomization, all patients will undergo multimodal CT or MRI at baseline. Only patients with a vessel occlusion (ICA or MCA) and penumbral tissue will be randomized.

The primary analysis is to compare the efficacy of tenecteplase versus placebo in all patients at Day 90.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE THROMBOLYSIS
Intervention  ICMJE
  • Biological: Tenecteplase
    The investigational medicinal product (IMP) for this study is tenecteplase. The recommended total dose for this study is weight-based with 0.25 mg of tenecteplase per kg, not exceeding a maximum dose of 25 mg. A single bolus dose should be administered over 5 seconds based on patient weight.
  • Other: Placebo
    Placebo is being used as the comparator since a thrombolytic is only FDA-approved in the United States for use out to 3 hours, and the standard of care guidelines support use out to 4.5 hours.
Study Arms  ICMJE
  • Experimental: Tenecteplase
    Patients in this arm will receive Tenecteplase (0.25 mg/kg, maximum 25 mg) administered as a single bolus injection over 5 seconds.
    Intervention: Biological: Tenecteplase
  • Placebo Comparator: Placebo
    Patients in this arm will receive placebo administered as a single bolus injection over 5 seconds.
    Intervention: Other: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: December 20, 2018)
456
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE April 30, 2022
Estimated Primary Completion Date November 30, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Age >= 18 years

  • AIS symptom onset within 4.5 to 24 hours Signs and symptoms consistent with the diagnosis of an acute anterior circulation ischemic stroke involving occlusion of the ICA, M1, or M2 vessels
  • Functionally independent (mRS 0-2) prior to stroke onset
  • Baseline NIHSS >=5 and that remains >=5 immediately prior to randomization
  • Neuroimaging: ICA or M1, M2 occlusion (carotid occlusions can be cervical or intracranial, with or without tandem MCA lesions) by MRA or CTA AND target mismatch profile on CT perfusion or MRI (ischemic core volume <70 mL, mismatch ratio is >=1.8 and mismatch volume is >= 15 mL)
  • The mismatch volume is determined by FDA-approved imaging software in real time based on the difference between the ischemic core lesion volume and the Tmax>6s lesion volume. If both a CT perfusion and a multimodal MRI scan are performed prior to enrollment, the later of the 2 scans is assessed to determine eligibility. Only an intracranial MRA is required for patients screened with MRA; cervical MRA is not required. Cervical and intracranial CTA are typically obtained simultaneously in patients screened with CTA, but only the intracranial CTA is required for enrollment.

Alternative neuroimaging:

  • If CTA (or MRA) is technically inadequate: Tmax>6s perfusion deficit consistent with an ICA or M1, M2 occlusion AND target mismatch profile (ischemic core volume <70 mL, mismatch ratio >= 1.8 and mismatch volume >= 15 mL as determined by RAPID software)
  • If magnetic resonance perfusion (MRP) is technically inadequate: ICA or M1, M2 occlusion (carotid occlusions can be cervical or intracranial; with or without tandem MCA lesions) by MRA (or CTA, if MRA is technically inadequate and a CTA was performed within 60 minutes prior to the MRI) AND diffusion-weighted imaging (DWI) lesion volume <=25 mL for an M1 or ICA occlusion and =<15 mL for an M2 occlusion
  • If CTP is technically inadequate: patient can be screened with MRI and randomized if neuroimaging criteria are met.
  • Ability to comply with the study protocol, in the investigator's judgment

Exclusion Criteria:

General

  • Current participation in another investigational drug or device study
  • Active internal bleeding
  • Known hypersensitivity or allergy to any ingredients of tenecteplase
  • Known bleeding diathesis
  • Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR >1.7
  • Use of one of the new oral anticoagulants within the last 48 hours (dabigatran, rivaroxaban, apixaban, edoxaban)
  • Pregnant
  • Intracranial neoplasm (except small meningioma), arteriovenous malformation, or aneurysm
  • Seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS
  • Severe, uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure > 110 mmHg)
  • For participants with suspected coagulopathy, platelet count must be checked prior to randomization and participant is excluded if baseline platelet count <100,000/microL
  • Baseline blood glucose >400 mg/dL (22.20 mmol/L)
  • Baseline blood glucose <50 mg/dL needs to be normalized prior to randomization
  • Clot retrieval attempted using a neurothrombectomy device prior to randomization
  • Intracranial or intraspinal surgery or trauma within 2 months
  • Treatment with a thrombolytic within the last 3 months prior to randomization
  • Other serious, advanced, or terminal illness (investigator judgment) with life expectancy less than 6 months
  • Pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluations
  • History of cerebrovascular accident in the last 90 days
  • Presumed septic embolus; suspicion of bacterial endocarditis
  • Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the patient if an endovascular procedure was to be performed

Imaging

  • Unable to undergo a contrast brain perfusion scan with either MRI or CT
  • Extensive early ischemic change (hypodensity) on non-contrast CT estimated to be >1/3 MCA territory, or significant hypodensity outside the Tmax>6s perfusion lesion that invalidates mismatch criteria (if patient is enrolled based on CT perfusion criteria)
  • Significant mass effect
  • Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA/MRA (e.g., bilateral MCA occlusions, or an MCA and a basilar artery occlusion)
  • Evidence of intracranial tumor (except small meningioma) acute intracranial hemorrhage, neoplasm, or arteriovenous malformation
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Reference Study ID Number: ML40787 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global-roche-genentech-trials@gene.com
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03785678
Other Study ID Numbers  ICMJE ML40787
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Genentech, Inc.
Study Sponsor  ICMJE Genentech, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Genentech, Inc.
Verification Date April 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP